Cytomyx reports rise in turnover and profits

Published: 31-Jan-2005

Cytomyx Holdings, a UK provider of drug discovery products and services, increased its turnover by 11% to


Cytomyx Holdings, a UK provider of drug discovery products and services, increased its turnover by 11% to £5.66m for the year ended 30 September, 2004.

Gross profit was up 32% at £3.38m, but the net loss increase to £915,661 (2003: £414,051), reflecting investment in new US operations; the acquisition of Clinomics Biosciences, a US company with a major collection of highly characterised human tissue samples; Clinomics' new oncology cell signalling database licensed to AstraZeneca; expansion in the number of ion channel cell lines from two to 17 and a collaboration with Moffit Cancer centre, Florida.

'We are delighted with the progress made during the year, reflected in the fact that we now work regularly for eight out of the top 10 pharmaceutical companies worldwide,' said Mike Kerins, Cytomyx ceo.

  

Trending Articles

You may also like